ArticleBMC geriatrics2026
Low-inflammatory response phenotypes in elderly urinary tract infections: pathogen type, antimicrobial resistance, and comorbidity-associated risk profiles.
Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prevalence and β-Lactam Resistance of Enterobacterales Isolated from Urinary Samples in a Regional Hospital in Poland: Special Emphasis on Elderly Population.Pathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urinary tract infections (UTIs) in elderly patients often present with attenuated inflammatory responses, complicating diagnosis and treatment. This retrospective cohort study analyzed 1,950 hospitalized patients aged ≥ 60 years (2022–2024) to investigate associations between uropathogens, antimicrobial resistance, urinary inflammatory markers (pyuria, leukocyte esterase, nitrite), and comorbidities. Standard culture, VITEK2 identification, and Clinical and Laboratory Standards Institute (CLSI) guidelines were used for pathogen characterization. Logistic regression models assessed risk factors for resistance and inflammation, while clinical outcomes were compared between susceptibility-matched and mismatched therapies.Escherichia coli dominated (62.7%) and elicited the strongest inflammatory responses, with pyuria (59.8%), leukocyte esterase (82.6%), and nitrite positivity (47.8%; all P < 0.001 compared with other pathogens). Enterococcus spp. (9.5%) and resistant strains (29.9%) showed significantly weaker inflammation: resistant isolates had lower pyuria (68.0% vs. 83.8%) and leukocyte esterase positivity (64.6% vs. 84.2%; P < 0.001). Diabetes independently increased risks of extended-spectrum β-lactamase (ESBL)-producing (OR = 1.87, 95% CI:1.50–2.33) and carbapenem-resistant Enterobacteriaceae (CRE) infections (OR = 2.01, 1.32–3.05), while chronic kidney disease correlated with Enterococcus prevalence (OR = 2.35, 1.54–3.59). Patients receiving susceptibility-matched therapy had shorter hospital stays (median 6 vs. 9 days, P = 0.025) and lower sepsis incidence (5.9% vs. 9.7%, P = 0.016).These findings reveal pathogen-specific inflammatory signatures in elderly UTIs, with resistant organisms and Enterococcus spp. linked to diagnostically challenging low-inflammatory phenotypes. Comorbidities shape resistance risks, advocating for individualized diagnostic thresholds and rapid resistance profiling to optimize empirical therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.